ASCO-CAP guidelines for breast predictive factor testing: an update

Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):499-500. doi: 10.1097/PAI.0b013e31822a8eac.

Abstract

This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor and Progesterone Receptor Testing by Immunohistochemistry, published in 2011.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology*
  • Early Detection of Cancer
  • Estrogen Receptor beta / immunology
  • Estrogen Receptor beta / metabolism
  • Female
  • Humans
  • Immunohistochemistry / methods
  • Immunohistochemistry / standards*
  • Practice Guidelines as Topic
  • Prognosis
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / metabolism
  • Receptors, Progesterone / immunology
  • Receptors, Progesterone / metabolism
  • Reference Standards
  • United States

Substances

  • Estrogen Receptor beta
  • Receptors, Progesterone
  • ERBB2 protein, human
  • Receptor, ErbB-2